Antimicrobial Activity of Ceftazidime-Avibactam (CAZ-AVI) among the Carbapenemase-Producing Gram-negative Rods Isolated from Clinical Samples
Journal of Medical Microbiology and Infectious Diseases · 2023
DOI: 10.61186/jommid.11.2.103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology and Infectious Diseases, 2023. Verfasst von Ravi Kumar Sharma und 2 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Introduction
Treating Gram-negative bacteria that produce extendedspectrum beta-lactamases (ESBLs), AmpC Beta lactamases, and carbapenemases is a significant clinical concern worldwide.To address this concern, Ceftazidime-Avibactam has been approved by the United States Food and Drug Administration (USFDA) as a practical option for combating multi-drug resistant (MDR) and extensively drug-resistant (XDR) organisms.Our study focused on determining the extent to which MDR Gram-negative organisms from various clinical samples exhibited resistance to CAZ-AVI.
Methods
Conducted at a central India tertiary care teaching hospital, our prospective study analyzed 258 Gram-negative bacteria specimens.These bacterial strains were identified using standard biochemical tests.ESBL production was detected using the combination disk method, while the AmpC enzyme was detected using the Epsilometer test (E-test).Furthermore, we assessed carbapenemase production using disk diffusion methods.Our study used the E-test to identify Metallo-betalactamases and Klebsiella pneumonia carbapenemase (KPC) activity.Additionally, we utilized the E-test to analyze the susceptibility patterns of CAZ-AVI.
Results
Of the 258 Gram-negative isolates studied, 214 (83%) were ESBL producers.Among these isolates, 90 (35%) showed evidence of AmpC beta-lactamase production, with 17 (19%) being pure AmpC producers and 73 (81%) being ESBL co-producers.55 (21.50%) were found to be carbapenemase producers.Among these isolates, 34 (62%) were MBL producers, while 11 (20%) were KPC producers.Of the carbapenemaseproducing isolates, 14 (25.50%) were resistant to CAZ-AVI.Among the MDR isolates, we found that CI 109 (90%), PB 118 (97.50%), and FO 113 (93.50%) were the most effective antimicrobial agents.
Conclusions
Gramnegative organisms that produce ESBL, AmpC, Carbapenemase, MBL, and KPC are particularly challenging for clinicians and a significant threat worldwide.However, our study results suggest that CAZ-AVI could be an effective standard therapy for managing MDR Gram-negative organisms.
Zitieren
APA
Sharma, R. K., Monica, M., & Chakraborty, A. (2023). Antimicrobial Activity of Ceftazidime-Avibactam (CAZ-AVI) among the Carbapenemase-Producing Gram-negative Rods Isolated from Clinical Samples. Journal of Medical Microbiology and Infectious Diseases. https://doi.org/10.61186/jommid.11.2.103
Vancouver
Sharma RK, Monica M, Chakraborty A. Antimicrobial Activity of Ceftazidime-Avibactam (CAZ-AVI) among the Carbapenemase-Producing Gram-negative Rods Isolated from Clinical Samples. Journal of Medical Microbiology and Infectious Diseases. 2023. doi:10.61186/jommid.11.2.103
BibTeX
@article{Sharma2023,
author = {Sharma, Ravi Kumar and Monica, Monica and Chakraborty, Arindam},
title = {Antimicrobial Activity of Ceftazidime-Avibactam (CAZ-AVI) among the Carbapenemase-Producing Gram-negative Rods Isolated from Clinical Samples},
journal = {Journal of Medical Microbiology and Infectious Diseases},
year = {2023},
doi = {10.61186/jommid.11.2.103}
}
EUVIMED